Abvc biopharma announces completion of subject recruitment for interim analysis on adhd phase iib clinical study

Fremont, ca, oct. 17, 2023 (globe newswire) -- via newmediawire –  abvc biopharma, inc . (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced an update on the company's eight-week long adhd phase iib clinical study taking place at the university of california san francisco (ucsf) medical center and five taiwanese medical centers. sixty-nine subjects enrolled in the study, 50 completed the study, and 11 are currently undergoing treatment.
ABVC Ratings Summary
ABVC Quant Ranking